Ubrogepant
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Ubrogepant is used to treat migraine disorders, migraine with aura and migraine without aura, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 23, 2019. In 2024, Medicare Part D spent $430 million on Ubrogepant across 328,000 claims for 83,000 beneficiaries.
Ubrogepant is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $108.89 to $109.11 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$108.89 – $109.11
per EA
7d Activity
avg -0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Allergan, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Calcitonin Gene-related Peptide Receptor Antagonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing UBROGEPANT
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
UBRELVY 100 MG TABLET | $109.1070 per EA | -0.03% |
UBRELVY 100 MG TABLET | $109.1070 per EA | -0.03% |
UBRELVY 50 MG TABLET | $108.8907 per EA | -0.02% |
Frequently Asked Questions
What is Ubrogepant used to treat?
Ubrogepant is used to treat migraine disorders, migraine with aura and migraine without aura, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Ubrogepant?
In 2024, Medicare Part D spent $430 million on Ubrogepant across 328,000 claims for 83,000 beneficiaries.
How many Ubrogepant products are on the market?
The Ubrogepant drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Ubrogepant?
NADAC reference prices for Ubrogepant range from $108.8907 to $109.1070 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Ubrogepant?
1 manufacturer lists Ubrogepant in NADAC. Ranked by number of NDCs, the largest are Allergan, Inc. (3).
How has the price of Ubrogepant changed recently?
Over the past 7 days, 0 Ubrogepant NDCs rose and 3 fell, with a market-wide average change of -0.0%.